Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blinded, Randomized, Placebo-controlled Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)

NCT05618691 is registered in ClinicalTrials.gov with Zhejiang Genfleet Therapeutics Co., Ltd. as lead sponsor.

NCT NCT05618691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05618691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blinded, Randomized, Placebo-controlled Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
Lead sponsor
Zhejiang Genfleet Therapeutics Co., Ltd.
Phase
Phase 2
Overall status
Withdrawn
Start date
December 1, 2022
Completion date
May 31, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intermittent claudication, peripheral artery disease